Arch Therapeutics, Inc.
Arch Therapeutics, Inc. (ARTH) Stock Ownership
Latest 13F position summary is not yet available — breakdown and tables fill in after filings publish (typically ~45 days after quarter end).
SEC 13F · FMP · ARTH · as of —
Ownership Breakdown
Institutional data for this period is not yet available. SEC Form 13F filings are typically published 45 days after quarter end.
No institutional data available for this period.
Insider Buying vs Selling
ARTH insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Aug 31, 2023 | Award | 20,584 | $1.00 | $20.6K | 20.6K | Form 4 ↗ |
ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Aug 31, 2023 | Purchase | 10,292 | $0.28 | $2.8K | 10.3K | Form 4 ↗ |
Norchi Terrence W PRESIDENT AND CHIEF EXECUTIVE | Aug 31, 2023 | Award | 13,724 | $1.00 | $13.7K | 13.7K | Form 4 ↗ |
Norchi Terrence W PRESIDENT AND CHIEF EXECUTIVE | Aug 31, 2023 | Purchase | 6,862 | $0.28 | $1.9K | 6.9K | Form 4 ↗ |
Hicks Laurence director | Aug 31, 2023 | Award | 20,584 | $1.00 | $20.6K | 20.6K | Form 4 ↗ |
Hicks Laurence director | Aug 31, 2023 | Purchase | 10,292 | $0.28 | $2.8K | 10.3K | Form 4 ↗ |
DHILLON PUNIT director | Nov 10, 2022 | Award | 250,000 | — | — | 250.0K | Form 4 ↗ |
Fish Guy L. director | Nov 10, 2022 | Award | 250,000 | — | — | 250.0K | Form 4 ↗ |
Hicks Laurence director | Nov 10, 2022 | Award | 250,000 | — | — | 250.0K | Form 4 ↗ |
Yrigoyen Dan VICE PRESIDENT, SALES | Nov 10, 2022 | Award | 500,000 | — | — | 500.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arch Therapeutics, Inc. (ARTH) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.
A total of 0 institutional investors currently hold ARTH stock, with a combined institutional value of approximately $0 as of the most recent 13F filing period.
Frequently asked questions
ARTH ownershipArch Therapeutics, Inc. (ARTH) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is — with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of —.